Perioperative gemcitabine + erlotinib plus pancreaticoduodenectomy for resectable pancreatic adenocarcinoma: ACOSOG Z5041 (Alliance) phase II trial

BACKGROUND: There is considerable interest in a neoadjuvant approach for resectable pancreatic ductal adenocarcinoma (PDAC). This study evaluated perioperative gemcitabine + erlotinib (G+E) for resectable PDAC. METHODS: A multicenter, cooperative group, single-arm phase II trial was conducted betwee...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Surg Oncol
Main Authors: Wei, Alice C., Ou, Fang-Shu, Shi, Qian, Carrero, Xiomara, O’Reilly, Eileen M., Meyerhardt, Jeffrey, Wolff, Robert A., Kindler, Hedy L., Evans, Douglas B., Deshpande, Vikram, Misdraji, Joseph, Tamm, Eric, Sahani, Dushyant, Moore, Malcolm, Newman, Elliot, Merchant, Nipun, Berlin, Jordan, Goff, Laura W., Pisters, Peter, Posner, Mitchell C.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6868305/
https://ncbi.nlm.nih.gov/pubmed/31418130
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1245/s10434-019-07685-1
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados